Market Overview

Jefferies' Aveo Pharmaceuticals Management Remains Confident in Differentiation From Inlyta


Jefferies published a research report concerning Aveo Pharmaceuticals (NASDAQ: AVEO) recent management meeting.

In the report, Jefferies states, “We had the opportunity to meet with AVEO management for an update on their thoughts post-release of top-line TIVO-1 results. We continue to believe that the 12-month progression free survival (PFS) and superior side effect profile will make tivo the new standard of care for renal cell carcinoma (RCC).”

Jefferies maintains its Buy rating and $30 PT on Aveo Pharmaceuticals, which closed Friday at $14.83.


Related Articles (PFS + AVEO)

View Comments and Join the Discussion!

Posted-In: JefferiesAnalyst Color News Price Target Management Analyst Ratings

Latest Ratings

PMTB of A SecuritiesMaintains18.5
IVRB of A SecuritiesMaintains3.0
EFCB of A SecuritiesMaintains15.5
NYMTB of A SecuritiesMaintains3.5
NLYB of A SecuritiesMaintains8.5
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at